Memorial Healthcare Institute for Neuroscience – Okemos
Location2525 Jolly Road, Suite 240
Okemos, MI 48864
Memorial Healthcare Institute for Neuroscience will be opening in Okemos in mid-March 2021!
At the Memorial Healthcare Institute for Neuroscience, we are passionate about delivering the very best care possible and take the time to understand each patient’s unique diagnosis and needs.
We believe in truly personalized care, delivered by experts trained in the complexities of a variety of difficult-to-understand neurological diseases and conditions.
Memorial Healthcare’s Institute for Neuroscience is world-renowned in the neurology field. Since 2015, Memorial Healthcare has been the first, or one of the first, hospitals in the State of Michigan to administer drug therapy treatments for its patients including Vypeti (for Migraines), Lemtrada (for MS), Ocrevus (for MS), Radicava (ALS), and Spinraza (for Spinal Muscular Atrophy). The Center offers patients the latest technology advances including NeuroQuant, a software that analyzes a brain MRI to improve the early detection and treatment of MS, dementia, Alzheimer’s disease, and epilepsy. Additionally, Memorial Healthcare is one of just three MDA care clinics in the State of Michigan.
Memorial Healthcare Institute for Neuroscience was the first in the United States to use neurofilament light (NfL) technology clinically for Multiple Sclerosis patients. “Once the blood test is approved it will completely change the way we practice neurology in the world, for not only MS, but also dementia and Alzheimer’s disease,” says Dr. Rany Aburashed, Chief of Neurology at the Institute for Neurosciences and MS.
The Institute was recognized as a Center for Comprehensive MS Care by the National MS Society in February 2020, one of just five holding this recognition in the State of Michigan.
Our highly skilled and experienced specialists handle the most complex MS cases with a patient load of over 2,400. We utilize the most advanced MRI technology in MS care and we are also home to MS research and clinical trials.